Date: 20-Aug-2019

Another hit for Roche UnitedHealthcare backs Amgen biosims over blockbuster oncology meds

Two of Roches oncology blockbusters are facing dire straits as first-ever biosimilar competitors have entered the U.S. market. Now, a major insurer is putting its money on the new guys.